Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients
| Autor: | Virinder Kaur Sarhadi, Maria P. Gomez, Zoe Dawson, Aino I. Telaranta-Keerie, Satu Mäki-Nevala, Mikko Rönty, Sakari Knuutila, Mike E. Morel, Aija Knuuttila |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Lung adenocarcinoma Male Lung Neoplasms medicine.medical_treatment DNA Mutational Analysis Gene mutation medicine.disease_cause Targeted therapy Pulmonary Disease Chronic Obstructive 0302 clinical medicine Carcinoma Non-Small-Cell Lung Epidermal growth factor receptor Finland EGFR inhibitors 0303 health sciences Mutation biology Smoking Exons Middle Aged 3. Good health ErbB Receptors Occupational Diseases Survival Rate 030220 oncology & carcinogenesis Adenocarcinoma Female Mutations Pulmonary and Respiratory Medicine medicine.medical_specialty EGFR Real-Time Polymerase Chain Reaction 03 medical and health sciences Sex Factors Internal medicine Occupational Exposure medicine Humans Lung cancer Survival rate 030304 developmental biology Aged business.industry Non–small-cell lung cancer Asbestos Frequency medicine.disease biology.protein business |
| Zdroj: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 9(6) |
| ISSN: | 1556-1380 |
| Popis: | Introduction: Among the driver gene mutations in non–small-cell lung cancer, mutations in epidermal growth factor receptor (EGFR) are the most important because of their predictive role in selecting patients eligible for targeted therapy. Our aim was to study EGFR mutations in a Finnish non–small-cell lung cancer cohort of 528 patients. Methods: Mutation testing was conducted on DNA extracted from paraffin-embedded, formalin-fixed tumor material using the following real-time polymerase chain reaction-based kits: Therascreen EGFR PCR Kit and cobas EGFR Mutation Test. Results: EGFR mutation frequency was 11.4% and all positive cases were adenocarcinomas, of which a majority had an acinar predominant pattern. Mutations were seen significantly more often in females and never-smokers than in males and smokers. The most frequent mutations were L858R in exon 21 and deletions in exon 19. Overall survival of the patients, not treated with EGFR inhibitor, did not differ between EGFR mutation-positive and EGFR mutation-negative patients. Conclusion: EGFR mutation profile in this Finnish non–small-cell lung cancer cohort resembles in many respect with that of other Western European cohorts, even though the overall frequency of mutations is slightly higher. We show the occurrence of EGFR mutations in patients with occupational asbestos exposure and also in those diagnosed with chronic obstructive pulmonary disease who have not been often investigated before. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|